Filtered By:
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 9821 results found since Jan 2013.

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5).
CONCLUSIONSBoth dulaglutide doses demonstrated superior glycemic control versus sitagliptin at 52 weeks with an acceptable tolerability and safety profile. PMID: 24742660 [PubMed - as supplied by publisher]
Source: Diabetes Care - April 17, 2014 Category: Endocrinology Authors: Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z Tags: Diabetes Care Source Type: research

Effects of selected antidiabetics on weight loss - A retrospective database analysis.
CONCLUSION: Our study showed that GLP-1 treatment was comparable to metformin regarding the weight reduction, while sulfonylurea and DPP-4 are inferior in this regard. PMID: 24815575 [PubMed - as supplied by publisher]
Source: Primary Care - May 6, 2014 Category: Primary Care Authors: Kostev K, Rex J, Rockel T, Heilmaier C Tags: Prim Care Diabetes Source Type: research

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes.
CONCLUSIONS: In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing the risk of hypoglycemia and with lower insulin requirements. PMID: 24929430 [PubMed - as supplied by publisher]
Source: Diabetes Care - June 14, 2014 Category: Endocrinology Authors: Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, on behalf of the EMPA-REG MDI Trial Investigators Tags: Diabetes Care Source Type: research

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients With Type 2 Diabetes and Coronary Artery Disease.
CONCLUSIONS: Our findings revealed the differential therapeutic effects of metformin and glipizide on comprehensive lipidomics, which were comparable with their different long-term effects on cardiovascular outcomes. PMID: 25011952 [PubMed - as supplied by publisher]
Source: Diabetes Care - July 10, 2014 Category: Endocrinology Authors: Zhang Y, Hu C, Hong J, Zeng J, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G, Xu G Tags: Diabetes Care Source Type: research

Glucagon-Like Peptide-1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Diabetes.
CONCLUSIONS: Adding exenatide to titrated glargine with metformin resulted in similar glycemic control as adding lispro and was well tolerated. These findings support exenatide as a noninsulin addition for patients failing basal insulin. PMID: 25011946 [PubMed - as supplied by publisher]
Source: Diabetes Care - July 10, 2014 Category: Endocrinology Authors: Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, for the 4B Study Group Tags: Diabetes Care Source Type: research

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy.
CONCLUSIONS: Dual inhibition of SGLT1/SGLT2 with LX4211 produced significant dose-ranging improvements in glucose control without dose-increasing glucosuria and was associated with reductions in weight and systolic BP in metformin-treated type 2 diabetes. PMID: 25216510 [PubMed - as supplied by publisher]
Source: Diabetes Care - September 11, 2014 Category: Endocrinology Authors: Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A Tags: Diabetes Care Source Type: research

Economic implications of weight change in patients with type 2 diabetes mellitus.
Conclusions Weight loss (> 3%) among patients with T2DM was associated with decreased costs and lower rates of treatment discontinuation. Hence weight-focused treatment approaches can help reduce the economic burden for patients with T2DM. PMID: 25295795 [PubMed - in process]
Source: The American Journal of Managed Care - October 12, 2014 Category: Health Management Authors: Bell K, Parasuraman S, Shah M, Raju A, Graham J, Lamerato L, D'Souza A Tags: Am J Manag Care Source Type: research

Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.
PMID: 25317361 [PubMed]
Source: Primary Care - October 17, 2014 Category: Primary Care Authors: Greg Deardorff O, Syed A, Ames CJ, Yaeger JS Tags: Prim Care Companion CNS Disord Source Type: research

Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
CONCLUSION: We evaluated the comparative efficacy of canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg on quality measure attainment after 52 weeks of treatment. Compared with sitagliptin 100 mg, canagliflozin 100 mg demonstrated comparable or superior attainment of diabetes-related quality measures. Compared with sitagliptin 100 mg, canagliflozin 300 mg demonstrated superior diabetes-related quality measure attainment, including glycemic, BP, and weight-related quality measures; there was no difference in LDL-C quality measure attainment between either dosage of canagliflozin and the 100-mg dosage of sita...
Source: The American Journal of Managed Care - December 1, 2014 Category: Health Management Authors: Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L Tags: Am J Manag Care Source Type: research

Association of Traditional Chinese Medicine Therapy and the Risk of Vascular Complications in Patients With Type II Diabetes Mellitus: A Nationwide, Retrospective, Taiwanese-Registry, Cohort Study
This study investigated whether the concurrent TCM treatment reduces the risk of vascular complications in T2DM patients by using a large population from National Health Insurance Research Database (NHIRD). We identified 33,457 adult patients with newly diagnosed T2DM using anti-diabetic agents from a random sample of one million beneficiaries in the NHIRD between January 1, 2000 and December 31, 2011. We recruited 1049 TCM users (received TCM over 30 days with a diagnosis of T2DM) and randomly selected 4092 controls as the non-TCM cohort at a ratio of 1:4 frequency-matched by age, sex, hypertension, hyperlipidemia, and i...
Source: Medicine - January 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Cost-benefit of appointment-based medication synchronization in community pharmacies.
CONCLUSIONS: ABMS programs have been shown to increase medication adherence in patients taking chronic medications. These programs were shown to have a significant cost-benefit for healthcare payers by reducing medical utilization and costs. Payers should consider supporting the provision of these programs in community pharmacies. PMID: 27662221 [PubMed - as supplied by publisher]
Source: The American Journal of Managed Care - August 31, 2016 Category: Health Management Authors: Patterson JA, Holdford DA, Saxena K Tags: Am J Manag Care Source Type: research

Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial
CONCLUSIONS Resveratrol supplementation does not improve hepatic or peripheral insulin sensitivity. Our results question the generalized value of resveratrol as an add-on therapy in the treatment of T2D and emphasize the need to perform studies in drug-naive patients with T2D or subjects with prediabetes.
Source: Diabetes Care - November 21, 2016 Category: Endocrinology Authors: Timmers, S.; de Ligt, M.; Phielix, E.; van de Weijer, T.; Hansen, J.; Moonen-Kornips, E.; Schaart, G.; Kunz, I.; Hesselink, M. K. C.; Schrauwen-Hinderling, V. B.; Schrauwen, P. Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research

A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
CONCLUSIONS: In current US clinical practice, patients receiving D + M ± OAD had greater reductions in important clinical outcomes of T2D-A1C level, weight loss, and blood pressure-versus patients receiving M + OAD. This study supports the use of dapagliflozin as add-on therapy to metformin with or without other OADs for patients with T2D. PMID: 29693359 [PubMed - in process]
Source: The American Journal of Managed Care - April 1, 2018 Category: Health Management Authors: Huang H, Bell KF, Gani R, Tugwell CW, Eudicone JM, Krukas-Hampel MR Tags: Am J Manag Care Source Type: research

Impact of formulary restrictions on medication intensification in diabetes treatment.
CONCLUSIONS: Part D formulary restrictions on sole-source brand name NIADs had little impact on patterns of treatment intensification for T2D among LIS recipients enrolled in Medicare Part D plans in 2012. PMID: 29851442 [PubMed - in process]
Source: The American Journal of Managed Care - May 1, 2018 Category: Health Management Authors: Stuart BC, Slejko JF, Rueda JD, Cooke C, Shen X, Roberto P, Ciarametaro M, Dubois R Tags: Am J Manag Care Source Type: research

Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
CONCLUSIONS: In the United States, sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with traditional treatment with generic medications for patients who fail to achieve glycemic goal on metformin. PMID: 31120717 [PubMed - in process]
Source: The American Journal of Managed Care - April 30, 2019 Category: Health Management Authors: Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G Tags: Am J Manag Care Source Type: research